Aethlon Medical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEMD research report →
Companywww.aethlonmedical.com
Aethlon Medical, Inc. , a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
- CEO
- James Frakes
- IPO
- 1999
- Employees
- 14
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $1.58M
- P/E
- -0.15
- P/S
- 0.00
- P/B
- 0.25
- EV/EBITDA
- 0.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -219.40%
- ROIC
- -103.33%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-13,388,089 · -9.66%
- EPS
- $-85.80 · -76.54%
- Op Income
- $-9,341,365
- FCF YoY
- 26.35%
Performance & Tape
- 52W High
- $34.40
- 52W Low
- $1.36
- 50D MA
- $2.18
- 200D MA
- $4.81
- Beta
- 1.50
- Avg Volume
- 58.77K
Get TickerSpark's AI analysis on AEMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Rossetti Angela | other | 21,815 |
| Apr 17, 26 | Shah Chetan | other | 21,815 |
| Apr 17, 26 | BROENNIMAN EDWARD G | other | 21,815 |
| Apr 17, 26 | Gikakis Nicolas | other | 21,815 |
| Mar 31, 26 | Shah Chetan | other | 178 |
| Mar 31, 26 | Gikakis Nicolas | other | 178 |
| Mar 31, 26 | BROENNIMAN EDWARD G | other | 89 |
| Dec 31, 25 | Shah Chetan | other | 179 |
| Dec 31, 25 | Gikakis Nicolas | other | 179 |
| Dec 31, 25 | BROENNIMAN EDWARD G | other | 89 |
Our AEMD Coverage
We haven't published any research on AEMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AEMD Report →